Switzerland-based Cytos Biotechnology (SIX: CYTN) on Friday said the company will be renamed Kuros Biosciences and that its chief executive Christian Itin will be stepping down from his position.
The transition is part of the restructuring ahead of the closing of acquisition of Kuros Biosurgery holding AG which is expected to take place within next few weeks.
Dr Itin will be replaced by Didier Cowling.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze